• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of cardiovascular translational research >Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale The FABOLUS FASTER Trial
【24h】

Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale The FABOLUS FASTER Trial

机译：促进通过橡皮皮或植物诱饵和普拉布雷的输注：ST升高的患者的多中心随机开放标签试验，患者心肌梗死初步经皮干预（FAGOLUS更快）试验：设计和理论面料较快试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Antithrombotic therapy is a critical component of the management of ST-elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (PCI). Rapid and profound inhibition of platelet reactivity has been shown to mitigate the ischemic risks and improve myocardial salvage. High residual platelet reactivity (HRPR) has been reported up to 4 or 6 h after loading dose of prasugrel or ticagrelor; therefore, multiple alternative strategies, including crushed or chewed oral tables or intravenous agents, have been investigated to provide a more rapid and sustained inhibition of platelet function and bridge the initial treatment gap. The FABOLUS FASTER is the first investigator-initiated, multicentre, open-label, prospective, randomized study to directly compare the pharmacodynamics effects of cangrelor, tirofiban, chewed or integer prasugrel. This study will add new insights in the management of antiplatelet therapy in patients with STEMI undergoing primary PCI and might be hypothesis-generating for future clinical trials in this field. The trial is registered on clinicaltrials.gov NCT02978040, and EudraCT 2017-001065-24.
机译：抗血栓治疗是ST段抬高型心肌梗死（STEMI）患者直接经皮冠状动脉介入治疗（PCI）治疗的关键组成部分。快速而深入地抑制血小板反应性已被证明可以减轻缺血风险并改善心肌挽救。据报道，高残留血小板反应性（HRPR）在负荷普拉格雷或替卡格雷4或6小时后出现；因此，研究了多种替代策略，包括压碎或咀嚼的口服片或静脉药物，以提供更快速和持续的血小板功能抑制，并弥合最初的治疗差距。FABOLUS FASTER是第一个由研究人员发起的、多中心、开放标签、前瞻性、随机研究，直接比较cangrelor、替罗非班、咀嚼或整粒普拉格雷的药效学效果。这项研究将为ST段抬高型心肌梗死患者接受直接PCI的抗血小板治疗的管理增加新的见解，并可能为该领域未来的临床试验产生假设。该试验已在临床试验中登记。政府NCT02978040和EudraCT 2017-001065-24。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号